Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.
Astellas Pharma Stock Performance
Astellas Pharma stock opened at $17.15 on Wednesday. The stock’s 50 day simple moving average is $15.44 and its two-hundred day simple moving average is $14.88. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.93 and a current ratio of 1.20. The stock has a market cap of $31.04 billion, a price-to-earnings ratio of 12.57 and a beta of 0.06. Astellas Pharma has a fifty-two week low of $12.21 and a fifty-two week high of $17.43.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.06). Astellas Pharma had a return on equity of 26.13% and a net margin of 16.18%. The firm had revenue of $3.98 billion for the quarter, compared to analysts’ expectations of $3.79 billion. As a group, analysts expect that Astellas Pharma will post 1.47 earnings per share for the current fiscal year.
About Astellas Pharma
Astellas Pharma Inc. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, and is headquartered in Tokyo. Astellas develops treatments across areas including oncology, urology, immunology and women’s health. Its medicines include Xtandi (enzalutamide), used to treat certain forms of prostate cancer, and Prograf (tacrolimus), an immunosuppressant used in organ transplantation.
See Also
- Five stocks we like better than Astellas Pharma
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
